

References

- Braun, T. (2020). Response and Resistance to BCR-ABL1-Targeted Therapies. *Cancer Cell*, 37(4). <https://www.sciencedirect-com.ezpv7-web-p-u01.wpi.edu/science/article/pii/S15361082030146X>
- Chen, M. (2017). Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effectively inhibiting the BCR-ABL-Tyr177-GRB2 complex. *Oncotarget Open Access Impact Journal*, 8(27). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546432/>
- Deininger, M. W., Goldman, J. M., & Melo, C. V. (2000). The role of BCR-ABL in the pathogenesis of chronic myeloid leukemia. *Blood*, 95(10), 3343-3356.
- Gorre, B. C., Mohammed, M., Ellwood, K., Grünwald, S., Espat, N. J., Majeti, R., ... & Sawyers, C. L. (2007). Identification of novel T315I BCR-ABL mutations in imatinib-resistant chronic myeloid leukemia. *Blood*, 109(2), 1079-1085.
- Hanfstein, B. (2014). Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. *Leukemia: London*, 28(10).
<https://www.proquest.com/docview/1609100946?accountid=29120&parentSessionId=UBRrweG9R%2F6xZNPv08IQ2mLvAABBft9LKZTA%2FTZmbg%3D&pq-origsite=primo>
- Jabbour, E., Khoury, H. J., Kantarjian, H., Saglio, G., Talpaz, M., & Deininger, M. W. (2019). Mechanisms of resistance to ABL kinase inhibitors in chronic myeloid leukemia. *Cancer discovery*, 9(12), 1451-1470.
- Laskowski, R. A., & Swindells, M. B. (2011). Macromolecular modeling with PyMOL. *Journal of molecular graphics & modeling*, 29(7), 627-628.

- Liu, Y. (2022). Higher-order interactions of Bcr-Abl can broaden chronic myeloid leukemia (CML) drug repertoire. *Protein Science*, 32(1).
<https://onlinelibrary-wiley-com.ezpv7-web-p-u01.wpi.edu/doi/full/10.1002/pro.4504>
- Ma, D. (2021). PKC- β /Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia. *Journal of Cellular Physiology*, 236(9).
<https://onlinelibrary-wiley-com.ezpv7-web-p-u01.wpi.edu/doi/full/10.1002/jcp.30301>
- MANNING, G. (2002). The Protein Kinase Complement of the Human Genome. *Science*, 298(5600). <https://www.science.org/doi/10.1126/science.1075762>
- Redaelli, S. (2012). Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors†. *American Journal of Hematology*, 87(11). <https://onlinelibrary.wiley.com/doi/10.1002/ajh.23338>
- Wang, J. (2020). Epigenetic Regulation of Differentially Expressed Drug-Metabolizing Enzymes in Cancer. *Aspet: Drug Metabolism and Disposition*, 48(9).
<https://dmd.aspetjournals.org/content/48/9/759>
- Zhang, J. (2010). Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. *Nature: London*, 463(7280).
<https://www.proquest.com/docview/204554831?accountid=29120&parentSessionId=vo2Bqn%2BWevJo0uGmyNkabHHBBLkqMwCYPMrLxwt74e%2Fk%3D&pq-origsite=pri>
- mo
- Zhou, H. (2017). Combined inhibition of β -catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. *Leukemia: London*, 31(10).
<https://www.proquest.com/docview/2615533360?accountid=29120&parentSessionId=t>

WSgt0Q2PR9xb20dyix%2FE5HQTc7uS6yHCi34spazos%3D&pq-origsite=prim